HK1040908B - Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders - Google Patents

Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders Download PDF

Info

Publication number
HK1040908B
HK1040908B HK02100988.2A HK02100988A HK1040908B HK 1040908 B HK1040908 B HK 1040908B HK 02100988 A HK02100988 A HK 02100988A HK 1040908 B HK1040908 B HK 1040908B
Authority
HK
Hong Kong
Prior art keywords
tofisopam
anxiety
disorder
composition
use according
Prior art date
Application number
HK02100988.2A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1040908A1 (en
Inventor
W. Landry Donald
F. Klein Donald
Original Assignee
Vela Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc. filed Critical Vela Pharmaceuticals Inc.
Publication of HK1040908A1 publication Critical patent/HK1040908A1/en
Publication of HK1040908B publication Critical patent/HK1040908B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK02100988.2A 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders HK1040908B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27
US60/105,803 1998-10-27
PCT/US1999/025040 WO2000024400A1 (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Publications (2)

Publication Number Publication Date
HK1040908A1 HK1040908A1 (en) 2002-06-28
HK1040908B true HK1040908B (en) 2005-04-22

Family

ID=22307874

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02100988.2A HK1040908B (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders
HK02106802.3A HK1046500A1 (zh) 1998-10-27 1999-10-27 旋光纯(r)tofisopam用於治疗和预防焦虑症的用途及其组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02106802.3A HK1046500A1 (zh) 1998-10-27 1999-10-27 旋光纯(r)tofisopam用於治疗和预防焦虑症的用途及其组合物

Country Status (16)

Country Link
EP (1) EP1124556B1 (enExample)
JP (2) JP2003522112A (enExample)
AT (1) ATE269705T1 (enExample)
AU (1) AU1451900A (enExample)
BR (1) BR9914899A (enExample)
CA (1) CA2348281A1 (enExample)
DE (1) DE69918322T2 (enExample)
DK (1) DK1124556T3 (enExample)
ES (1) ES2224751T3 (enExample)
GB (1) GB2367748A (enExample)
HK (2) HK1040908B (enExample)
IL (2) IL142803A0 (enExample)
NZ (1) NZ511744A (enExample)
PT (1) PT1124556E (enExample)
WO (1) WO2000024400A1 (enExample)
ZA (1) ZA200103376B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US7745431B2 (en) 2002-12-03 2010-06-29 Vela Acquisition Corporation Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
WO2004069155A2 (en) * 2002-12-03 2004-08-19 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
WO2005056017A1 (en) * 2003-12-03 2005-06-23 Vela Pharmaceuticals, Inc. Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) * 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Also Published As

Publication number Publication date
ZA200103376B (en) 2003-09-09
EP1124556A1 (en) 2001-08-22
GB0111739D0 (en) 2001-07-04
EP1124556B1 (en) 2004-06-23
ATE269705T1 (de) 2004-07-15
BR9914899A (pt) 2001-07-17
IL142803A0 (en) 2002-03-10
JP2003522112A (ja) 2003-07-22
NZ511744A (en) 2004-04-30
GB2367748A (en) 2002-04-17
DE69918322T2 (de) 2005-09-15
CA2348281A1 (en) 2000-05-04
PT1124556E (pt) 2004-10-29
WO2000024400A1 (en) 2000-05-04
IL142803A (en) 2006-10-05
JP2007211028A (ja) 2007-08-23
DE69918322D1 (de) 2004-07-29
ES2224751T3 (es) 2005-03-01
AU1451900A (en) 2000-05-15
DK1124556T3 (da) 2004-10-11
HK1046500A1 (zh) 2003-01-17
GB2367748A8 (en) 2002-12-19
HK1040908A1 (en) 2002-06-28

Similar Documents

Publication Publication Date Title
US6080736A (en) Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
JP2007211028A (ja) 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物
Fasipe The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents
Cohen et al. Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice
Elko et al. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction
CN110996947A (zh) N-甲基-d-天冬氨酸型谷氨酸受体拮抗剂反应性神经精神性疾病的联合治疗
EP2185155A1 (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
WO2008070000A2 (en) Treatment of anxiety with eszopiclone
US8735389B2 (en) Treating psychological conditions using muscarinic receptor M1 antagonists
IL149134A (en) Pharmaceutical compositions containing tofisopam
Ciraulo et al. Sedative hypnotics
Pinder Designing a new generation of antidepressant drugs
AU2005201012A1 (en) Use of Optically Pure (R)-Tofisopam for Treating and Preventing Anxiety Disorders and Composition Thereof
KR102609676B1 (ko) Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료
Fasipe Moving from the old monoaminergic theory toward the emerging hypothesis in the rational design of rapid-onset novel antidepressants
Fasipe et al. Announcing the first novel class of rapid-onset antidepressants in clinical practice
Shelton Serotonin norepinephrine reuptake inhibitors: similarities and differences
MXPA01004109A (en) Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof
Preskorn et al. Other antidepressants

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081027